Patent Assignment
Reel/Frame 027192/0334
Security Agreement
Recorded: 2011-11-08
Received: 2011-11-08
Pages: 11
Assignor
AMYLIN PHARMACEUTICALS, INC.
Executed: 2011-11-07
Assignee
ELI LILLY AND COMPANY
LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 46285, UNITED STATES
Covered Properties
(51)
Exendins and Exendin Agonist Analogs to Regulate Gastrointestinal Motility
Application:
13/226,975 →
Methods for Treating Diabetes with Extended Release Formulations of Glp-1 Receptor Agonists
Application:
61/501,018 →
Methods of using GLP-1 receptor agonists to treat pancreatitis
Application:
13/155,211 →
Sustained Release Formulations Using Non-Aqueous Carriers
Application:
13/060,225 →
Methods for Treating Diabetes and Reducing Body Weight
Application:
13/084,757 →
Methods of Treatment Using Exendin Peptides or Glp-1 Peptides
Application:
13/080,051 →
Methods for Lowering Plasma Glucagon with Exendins and Exendin Agonist Analogs
Application:
13/045,334 →
Exendins to Lower Cholesterol and Triglycerides
Application:
12/992,060 →
DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties
Application:
12/377,856 →
GLP-1 Receptor Agonists for Islet Cell Transplantation
Application:
61/426,076 →
Glp-1 Receptor Agonist Bioassays
Application:
12/990,693 →
Treatment of Hibernating Myocardium with an Exendin Peptide
Application:
12/945,702 →
Exendin and Exendin Agonists for Eating Disorders
Application:
12/766,195 →
Treatment of Cardiac Arrhythmias
Application:
12/750,575 →
Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same
Application:
12/640,352 →
Use of Exendins and Exendin Agonists and Glp-1 Receptor Agonists for Altering the Concentration of Fibrinogen
Application:
12/375,734 →
Use of Glp-1 and Agonists Thereof to Prevent Cardiac Myocyte Apoptosis
Application:
11/857,951 →
Polymer-Based Sustained Release Device
Application:
12/483,871 →
Hybrid Polypeptides with Selectable Properties
Application:
12/063,420 →
Exendin-4 to Treat Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease
Application:
12/063,712 →
Lyophilized Formulations of Exendins and Exendin Agonist Analogs
Application:
12/389,509 →
Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases
Application:
12/294,235 →
Exendins and Exendin Agonist Analogs to Regulate Gastrointestinal Motility
Application:
12/353,861 →
Methods to Restore Glycemic Control
Application:
12/298,933 →
Methods of Treatment Using Exendin Peptides or Glp-1 Peptides
Application:
12/247,141 →
Use of Exendin and Analogs Thereof To Delay or Prevent Cardiac Remodeling
Application:
11/910,730 →
Methods of Controlling Binge Eating Disorders
Application:
11/910,214 →
Poly(Lactide-Co-Glycolide) Based Sustained Release Microcapsules Comprising a Polypeptide and a Sugar
Application:
11/578,712 →
Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus
Application:
11/869,013 →
Pharmaceutical Formulations Comprising Incretin mimetic Peptide and Aprotic Polar Solvent
Application:
11/910,723 →
Transmucosal delivery of peptides and proteins
Application:
11/628,123 →
Polymer-Based Sustained Release Device
Application:
11/521,091 →
Methods and Compositions for Treating Polycystic Ovary Syndrome
Application:
11/518,574 →
Novel Methods and Compositions for Enhanced Transmucosal Delivery of Peptides and Proteins
Application:
10/559,595 →
Compositions and Methods for Treating Peripheral Vascular Disease
Application:
11/198,527 →
Use of Exendins and Agonists Thereof for Lowering Plasma Lipid
Application:
10/966,337 →
Metabolic Intervention with Glp-1 or Its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain
Application:
10/913,309 →
Exendin Pharmaceutical Compositions
Application:
10/896,244 →
Exendins and Exendin Agonists for Weight Reduction and Obesity
Application:
10/895,909 →
Pharmaceutical Compositions Containing Exendins
Application:
10/894,999 →
Method for Enhanced Parenteral Nutrition
Application:
10/842,933 →
Treatment of Cardiac Arrhythmias with Glp-1 Receptor Ligands
Application:
10/740,146 →
Methods and Compositions for Treating Polycystic Ovary Syndrome
Application:
10/629,649 →
Treatment of Acute Coronary Syndrome with Exendin-4
Application:
10/322,839 →
Methods and Compositions for Treating Polycystic Ovary Syndrome
Application:
10/317,126 →
Exendins, Exendin Agonists, and Methods for Their Use
Application:
10/187,051 →
Compositions and Methods for Treating Peripheral Vascular Disease
Application:
10/091,258 →
Novel Exendin Agonist Formulations and Methods of Administration Thereof
Application:
09/889,330 →
Methods for Glucagon Suppression
Application:
09/889,331 →
Methods of Treating Obesity Using Pyy[3-36]
Application:
10/016,969 →
Metabolic Intervention with Glp-1 to Improve the Function of Ischemic and Reperfused Tissue
Application:
09/851,738 →